… presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, … editing in humans. In addition, his group has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
… group? I joined the DEI team in 2023 to contribute to developing our inclusive culture. In 2023, ProQR’s … is for everyone, and we’re committed to providing a safe, open, inclusive, and inspiring workplace. During Pride Month (in June) our company logo adopts beautiful rainbow colors in support of the LGBTQIA+ …
… in raising awareness and trying to generate change for people worldwide living with a rare disease, their families, … on rare diseases, working towards equity in social opportunity, healthcare, and access to diagnosis and … Principal Researcher at ProQR "I work on designing and optimizing new therapies" Nanyamka Braham from Regulatory …
… Team. During the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial pipeline targets for internal development, and provide guidance on the advancement of … has led in the development of structure-guided methods for optimizing chemically modified oligonucleotides for …
… are a true believer of the value of a workforce in which people from diverse backgrounds are encouraged to develop themselves, personally and professionally. We believe that happy and energized people, working well together in an environment in which they …
… AX-1412 B4GALT1 Cardiovascular disease 2025 update on optimization for GalNAc delivery Continue to execute on … milestone income from the existing partnership, and an option to exercise for an additional five targets for … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. Financial Highlights At June 30, …
… B4GALT1 for Cardiovascular diseases mid-2025 update on optimization for GalNAc delivery Continue to execute on … milestone income from the existing partnership, and an option to exercise for an additional five targets for … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
… lives through transformative RNA therapies based on its proprietary Axiomer RNA editing technology platform, today … Advisory Board. As Chief ADAR Scientist, he drives the development and optimization of the Company’s Axiomer … a total of 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
… pipeline program, QR-504a for Fuchs endothelial corneal dystrophy, is expected to advance to clinical testing in the … visual acuity, visual fields, and the objective measure of optical coherence tomography (OCT) retinal imaging, after a … The closing included the full exercise of underwriters’ option to purchase 2,076,923 additional shares. Gross …
… biomarker bile acids 72 hours after treatment. Further optimizations for EONs targeting NTCP have enabled … AX-0810 targeting NTCP for cholestatic diseases: clinical development candidate translational data to be reported, and … of deal to 15 targets, which would result in a $50 million opt-in payment to ProQR. ProQR may selectively form new …
